Methods for treating cartilage disorders, diseases and injuries

The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. 19.-. (canceled)10. A method for treating cartilage diseases , disorders and injuries in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a composition selected from the group consisting of a Cellular Factor-containing Solution (CFS) composition , Amnion-derived Multipotent Progenitor (AMP) cells , AMP-nucleus pulposus (NP) cells and AMP-annulus fibrosus (AF) cells.11. The method of wherein the treatment reduces the inflammation associated with cartilage diseases claim 10 , disorders and injuries.12. The method of wherein the CFS composition is selected from the group consisting of Amnion-derived Cellular Cytokine Solution (ACCS) claim 10 , ACCS-nucleus pulposus (NP) and ACCS-annulus fibrosus (AF).13. The method of wherein the cartilage disease claim 10 , disorder or injury is selected from the group consisting of osteoarthritis claim 10 , rheumatoid arthritis claim 10 , gouty arthritis claim 10 , psoriatic arthritis claim 10 , intervertebral disc herniation claim 10 , degenerative disc disease claim 10 , spinal stenosis claim 10 , lumbar scoliosis claim 10 , chondrodystrophies claim 10 , traumatic rupture or detachment claim 10 , achondroplasty claim 10 , costochondritis claim 10 , relapsing polychonditis destruction claim 10 , and ankylosing spondylitis.14. A method for promoting the growth or enhancing the survival of NP cells in a degenerating intervertebral disc comprising administering to the degenerating intervertebral disc a ...

Methods for treating hidradenitis suppurativa

The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions). 117.-. (canceled)18. A method for reducing inflammation associated with Hidradenitis Suppurativa (HS) in a patient in need thereof comprising topically administering or injecting into the affected area about 0.1-to-1000 micrograms per square centimeter of applied area an Extracellular Cytokine-containing Solution (ECS) composition such that inflammation associated with HS is reduced , wherein the ECS composition comprises about 5-16 ng/mL VEGF , about 3.5-4.5 ng/mL Angiogenin , about 100-165 pg/mL PDGF , about 2.5-2.7 ng/mL TGFβ2 , about 0.68 μg/mL TIMP-1 and about 1.04 μg/mL TIMP-2.19. The method of wherein the ECS composition is formulated for topical administration.20. The method of wherein the ECS composition is formulated for sustained-release.21. The method of wherein the ECS composition is administered in combination with another agent and/or treatment modality.22. The method of wherein the ECS composition is Amnion-derived Cellular Cytokine Solution (ACCS).23. The method of wherein the ACCS is formulated for topical administration.24. The method of wherein the ACCS is formulated for sustained-release.25. The method of wherein the ACCS is administered in combination with another agent and/or treatment modality. The field of the invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the field of the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa and promoting healing of wounds associated with Hidradenitis ...

Compositions and methods for modulating ischemic injury

The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents.

Methods for accelerating the healing of connective tissue injuries and disorders

The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS). 1. A method for accelerating the healing of connective tissue injuries or disorders in a patient in need thereof comprising administering to the patient a therapeutically effective amount of one or more compositions selected from the group consisting of extraembryonic cytokine-secreting (ECS) cells , conditioned media derived therefrom , cell lysate derived therefrom , cell products derived therefrom , and Physiologic Cytokine Solution (PCS).2. The method of wherein the connective tissue injury and disorder is selected from the group consisting of tears claim 1 , ruptures claim 1 , sprains claim 1 , strains claim 1 , contusions claim 1 , tendinitis/tendinosis claim 1 , avulsions claim 1 , bursitis claim 1 , tenosynovitis claim 1 , stress fractures and surgery.3. The method of wherein the ECS cells are Amnion-derived Multipotent Progenitor (AMP) cells.4. The method of wherein the conditioned medium is Amnion-derived Cellular Cytokine Solution (ACCS) or pooled ACCS.5. The method of wherein the ACCS and pooled ACCS is formulated for sustained-release.6. The method of wherein the ECS cells claim 1 , conditioned media derived therefrom claim 1 , cell lysate derived therefrom or cell products derived therefrom are administered in combination with other agents or treatment modalities.7. The method of wherein the other ...

Modeling Wound Healing

Provided are methods of simulating tissue healing. The methods comprise using a mechanistic computer model of the interrelated effects of inflammation, tissue damage or dysfunction and tissue healing to predict an outcome of healing of damaged tissue in vivo, thereby predicting the outcome of healing of damaged tissue in vivo. Implementations of these methods on a computing device also are provided. Non-limiting examples of diseases and/or conditions that are amenable to simulation according to the methods described herein include: a diabetes, diabetic foot ulcers, necrotizing enterocolitis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, restenosis (post-angioplasty or stent implantation), incisional wounding, excisional wounding, surgery, accidental trauma, pressure ulcer, stasis ulcer, tendon rupture, vocal fold phonotrauma, otitis media and pancreatitis.

Wound Healing Device

The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix. 111.-. (canceled)12. A skin wound healing device for topical administration comprising a cloth which is embedded with a skin wound healing composition , wherein the skin wound healing composition consists of protein factors selected from the group consisting of physiologic levels of VEGF , Angiogenin , PDGF , TGFβ2 , TIMP-1 and TIMP-2 that are dissolved in a carrier , wherein the physiologic levels are ˜5-16 ng/mL for VEGF , ˜3.5-4.5 ng/mL for Angiogenin , ˜100-165 pg/mL for PDGF , ˜2.5-2.7 ng/mL for TGFβ2 , ˜0.68 μg/mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2.13. The skin wound healing device of wherein the cloth has the property of hemostatic activity and/or anti-infectious agent and/or antibacterial activity.14. The skin wound healing device of wherein the cloth is made of a natural claim 12 , plant-derived fiber.15. The skin wound healing device of wherein the plant-derived fiber has a rough surface.16. The skin wound healing device of which has been irradiated to achieve sterility.17. The skin wound healing device of which is contained in a sterile package.18. The skin wound healing device of wherein the cloth is made of a natural claim 12 , plant-derived fiber and another fiber or material selected from the group consisting of glass claim 12 , Teflon® claim 12 , Gor-Tex® claim 12 , hair and feathers.19. The skin wound healing device of wherein the carrier is selected from the group consisting of normal saline claim 12 , PBS claim 12 , lactated Ringer's solution and cell culture medium. This application is a divisional application of U.S. application Ser. No. 13/134,881, filed Jun. 20, 20011 and claims priority under 35 USC §119(e) of U.S. Provisional Application No. 61/398,167, filed Jun. 22, 2010, and U.S. Provisional Application No. 61/398,751, filed Jun. 30, 2010, the ...

Methods for accelerating the healing of connective tissues injuries and disorders

The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS). 19.-. (canceled)10. A method for accelerating the healing of connective tissue injuries or disorders in a patient in need thereof comprising administering to the patient a therapeutically effective amount of one or more compositions selected from the group consisting of extraembryonic cytokine-secreting (ECS) cells , cell lysate derived therefrom , cell products derived therefrom , and Physiologic Cytokine Solution (PCS).11. The method of wherein the connective tissue injury and disorder is selected from the group consisting of tears claim 10 , ruptures claim 10 , sprains claim 10 , strains claim 10 , contusions claim 10 , tendinitis/tendinosis claim 10 , avulsions claim 10 , bursitis claim 10 , tenosynovitis claim 10 , stress fractures and surgery.12. The method of wherein the ECS cells are Amnion-derived Multipotent Progenitor (AMP) cells.13. The method of wherein the ECS cells claim 10 , cell lysate derived therefrom or cell products derived therefrom are administered in combination with other agents or treatment modalities.14. The method of wherein the other agents are active agents.15. The method of wherein the active agents are selected from the group consisting of growth factors claim 14 , cytokines claim 14 , inhibitors claim 14 , immunosuppressive agents claim 14 , steroids claim 14 , chemokines claim 14 ...

Wound Healing Device and Method

The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof. 116.-. (canceled)17. A wound healing device for healing incisional wounds comprising a suture or knitted mesh which is embedded with a wound healing composition , wherein the wound healing composition consists of protein factors selected from the group consisting of physiologic levels of VEGF , Angiogenin , PDGF , TGFβ2 , TIMP-1 and TIMP-2 that are dissolved in a carrier , wherein the physiologic levels are ˜5-16 ng/mL for VEGF , ˜3.5-4.5 ng/mL for Angiogenin , ˜100-165 pg/mL for PDGF , ˜2.5-2.7 ng/mL for TGFβ2 , ˜0.68 μg/mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2.18. The wound healing device of wherein the suture or knitted mesh is braided.19. The wound healing device of wherein the suture is nonabsorbable or bioerodable and the knitted mesh is bioerodable.20. The wound healing device of wherein the bioerodable suture or knitted mesh is made of polyglycolic acid claim 19 , polyglutamic acid claim 19 , polydioxanone claim 19 , polylactide claim 19 , or caprolactone.21. The wound healing device of wherein the nonabsorbable suture is made of nylon claim 19 , polyester claim 19 , polypropylene or silk.22. The wound healing device of which is contained in a sterile package.23. The wound healing device of wherein the carrier is selected from the group consisting of normal saline claim 17 , PBS claim 17 , lactated Ringer's solution and cell culture medium. This application is a divisional application of U.S. application Ser. No. 13/374,825, filed Jan. 17, 2012 and claims priority under 35 USC §119(e) of U.S. Provisional ...

Compositions and methods for modulating ischemic injury

The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents.

Modulating Ischemic Injury

The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.

MODULATING ISCHEMIC INJURY

The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents. 1. A method for modulating ischemic injury in tissues or organs , the method comprising the step of perfusing and/or immersing the tissue or organ with a composition comprising Amnion-derived Cellular Cytokine Solution (ACCS).2. The method of wherein the ACCS is formulated for sustained-release claim 1 , targeted-release claim 1 , timed-release claim 1 , or extended-release.3. The method of wherein the tissue or organ is a donated tissue or organ intended for transplant.4. The method of wherein the tissue is selected from the group consisting of epithelial tissue claim 1 , connective tissue claim 1 , muscle tissue and nervous tissue.5. The method of wherein the organ is selected from the group consisting of heart claim 1 , blood vessel claim 1 , alimentary canal claim 1 , stomach claim 1 , liver claim 1 , pancreas claim 1 , spleen claim 1 , kidney claim 1 , lung claim 1 , trachea claim 1 , cornea claim 1 , lens claim 1 , eye claim 1 , bladder claim 1 , ureter claim 1 , urethra claim 1 , uterus claim 1 , ovary claim 1 , testis claim 1 , nerve claim 1 , skin claim 1 , tooth claim 1 , and skeletal muscle.6. A method for reducing ischemic injury in tissues or organs claim 1 , the method comprising the step of perfusing and/or immersing the tissue or organ with a composition comprising ACCS.7. The method of wherein the ...

Modulating Ischemic Injury

The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.

Methods for treating hidradenitis suppurativa

The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions). 1. A method for treating Hidradenitis Suppurativa (HS) in a patient in need thereof comprising topically administering to the patient a therapeutically effective amount of a Cellular Factor-containing Solution (CFS) composition.2. The method of wherein the CFS composition is Amnion-derived Cellular Cytokine Solution (ACCS).3. The method of wherein the CFS composition claim 1 , including ACCS claim 1 , is formulated for topical administration.4. The method of wherein the CFS composition claim 1 , including ACCS claim 1 , is formulated for sustained-release.5. The method of wherein the CFS is administered in combination with another agent and/or treatment modality.6. A method for reducing inflammation associated with HS in a patient in need thereof comprising topically administering to the patient a therapeutically effective amount of a CFS composition such that inflammation associated with HS is reduced.7. The method of wherein the CFS composition is Amnion-derived Cellular Cytokine Solution (ACCS).8. The method of wherein the CFS composition claim 6 , including ACCS claim 6 , is formulated for topical administration.9. The method of wherein the CFS composition claim 6 , including ACCS claim 6 , is formulated for sustained-release.10. The method of wherein the CFS is administered in combination with another agent and/or treatment modality.11. A method for promoting the healing of non-healing wounds associated with HS in a patient in need thereof comprising topically administering to the patient a ...

Modulating ischemic injury and preserving/storing tissue

The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents. 120.-. (canceled)21. A method for modulating ischemic injury in donated tissues or organs that have been harvested for transplant , the method comprising the step of perfusing and/or immersing the donated tissue or organ with a composition comprising Amnion-derived Cellular Cytokine Solution (ACCS).22. The method of wherein the ACCS is formulated for sustained-release claim 21 , targeted-release claim 21 , timed-release claim 21 , or extended-release.23. The method of wherein the tissue is selected from the group consisting of epithelial tissue claim 21 , connective tissue claim 21 , muscle tissue and nervous tissue and the organ is selected from the group consisting of heart claim 21 , blood vessel claim 21 , alimentary canal claim 21 , stomach claim 21 , liver claim 21 , pancreas claim 21 , spleen claim 21 , kidney claim 21 , lung claim 21 , trachea claim 21 , cornea claim 21 , lens claim 21 , eye claim 21 , bladder claim 21 , ureter claim 21 , urethra claim 21 , uterus claim 21 , ovary claim 21 , testis claim 21 , nerve claim 21 , skin claim 21 , tooth claim 21 , and skeletal muscle.24. A method for reducing ischemic injury in donated tissues or organs that have been harvested for transplant claim 21 , the method comprising the step of perfusing and/or immersing the donated tissue or organ with a composition ...

Methods for accelerating the healing of connective tissue injuries and disorders

The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS). 19.-. (canceled)10. A method for accelerating the healing of connective tissue injuries or disorders in a patient in need thereof comprising administering to the patient a therapeutically effective amount of Physiologic Cytokine Solution (PCS).11. The method of wherein the connective tissue injury and disorder is selected from the group consisting of tears claim 10 , ruptures claim 10 , sprains claim 10 , strains claim 10 , contusions claim 10 , tendinitis/tendinosis claim 10 , avulsions claim 10 , bursitis claim 10 , tenosynovitis claim 10 , stress fractures and surgery.12. The method of wherein the PCS is administered in combination with other agents or treatment modalities.13. The method of wherein the other agents are active agents.14. The method of wherein the active agents are selected from the group consisting of growth factors claim 13 , cytokines claim 13 , inhibitors claim 13 , immunosuppressive agents claim 13 , steroids claim 13 , chemokines claim 13 , antibodies claim 13 , antibiotics claim 13 , antifungals claim 13 , antivirals claim 13 , mitomycin C claim 13 , and other cell types.15. The method of wherein the other treatment modalities are selected from the group consisting of rest claim 12 , ice claim 12 , compression claim 12 , elevation claim 12 , exercise and physical therapy. This application ...

Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury

The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light. 111.-. (canceled)12. A method for reducing the extent of laser-induced tissue burns , the method comprising the step of applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue following exposure to the laser.13. A method for reducing the extent of laser-induced tissue burns , the method comprising the step of applying a therapeutically effective amount of ACCS to the tissue prior to exposure to the laser.14. The method of or wherein the ACCS is formulated for topical , intranasal , intradermal , subdermal , subcutaneous , subconjunctival , intravitreal , or intraocular administration.15. The method of or wherein the ACCS is applied within 90 minutes of exposure to the laser.16. The method of or wherein the tissue is selected from the group consisting of skin , mucous membrane , cornea , lens and retina.17. The method of wherein in the skin is selected from the group consisting of scarred skin claim 16 , tattooed skin claim 16 , abnormally pigmented skin claim 16 , and skin having psoriatic lesions.18. The method of wherein the skin is undergoing exfoliation or skin resurfacing.19. The method of or wherein the laser is selected from the group consisting of gas lasers claim 16 , chemical lasers claim 16 , dye lasers claim 16 , metal vapor lasers claim 16 , solid-state lasers claim 16 , semiconductor lasers claim 16 , and UV lasers. The field of the invention is directed to methods for reducing the extent of light-induced tissue injury resulting from exposure to a light. The method comprises applying a therapeutically effective amount ...

Methods for preventing or treating necrotizing enterocolitis

The invention is directed to methods for preventing and/or treating necrotizing enterocolitis. The invention is further directed to reducing inflammation of the intestinal mucosa associated with necrotizing enterocolitis. The invention is further directed to methods for preventing and/or treating necrotizing enterocolitis and/or inflammation of the intestinal mucosa associated with necrotizing enterocolitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions). 1. A method for preventing necrotizing enterocolitis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a CFS composition.2. The method of wherein the CFS composition is ACCS.3. The method of wherein the CFS composition is formulated for an administration route selected from the group consisting of enteral administration claim 1 , intravenous administration claim 1 , and intraperitoneal administration.4. The method of wherein the CFS composition that is formulated for enteral administration includes a nutritive infant formula.5. The method of wherein the CFS composition is formulated for sustained-release.6. A method for treating necrotizing enterocolitis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a CFS composition.7. The method of wherein the CFS composition is ACCS.8. The method of wherein the CFS composition is formulated for an administration route selected from the group consisting of enteral administration claim 6 , intravenous administration claim 6 , and intraperitoneal administration.9. The method of wherein the CFS composition that is formulated for enteral administration includes a nutritive infant formula. ...

Methods for preventing or treating optic neuritis

The invention is directed to methods for preventing and/or treating optic neuritis. The invention is further directed to reducing inflammation associated with the development of optic neuritis. The invention is further directed to methods for preventing and/or treating optic neuritis and/or inflammation associated with the development of optic neuritis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel immediate-release, targeted-release, and sustained-release (SR) cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions. 1. A method for preventing or treating optic neuritis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a composition selected from the group consisting of a CFS composition and Amnion-derived Multipotent Progenitor (AMP) cells.2. The method wherein the CFS composition is ACCS.3. The method of wherein the CFS composition or the AMP cells are formulated for intranasal administration.4. The method of wherein the intranasal administration is aerosol or spray administration.5. The method of wherein the CFS composition or the AMP cells are contained in a nasal packing material.6. The method of wherein the CFS composition is formulated as a lyophilized dry powder nasal formulation.7. A method for reducing inflammation associated with the development of optic neuritis in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a composition selected from the group consisting of a CFS composition and Amnion-derived Multipotent Progenitor (AMP) cells such that inflammation associated with the development of optic neuritis is reduced.8. The method wherein the CFS composition is ACCS ...

Modulating ischemic injury and preserving/storing tissue

The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.

Methods for preventing or treating optic neuritis

The invention is directed to methods for preventing and/or treating optic neuritis. The invention is further directed to reducing inflammation associated with the development of optic neuritis. The invention is further directed to methods for preventing and/or treating optic neuritis and/or inflammation associated with the development of optic neuritis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel immediate-release, targeted-release, and sustained-release (SR) cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions. 112.-. (canceled)13. A method for preventing or treating optic neuritis in a patient in need thereof comprising intranasally administering to the patient a therapeutically effective amount of a composition selected from the group consisting of (Amnion-derived Cellular Cytokine Solution (ACCS) and Amnion-derived Multipotent Progenitor (AMP) cells.14. The method of wherein the ACCS or the AMP cells are formulated for intranasal administration.15. The method of wherein the intranasal administration is aerosol or spray administration.16. The method of wherein the ACCS or the AMP cells are contained in a nasal packing material.17. The method of wherein the ACCS is formulated as a lyophilized dry powder nasal formulation.18. The method of wherein the intranasal administration comprises the steps ofa) delivering the ACCS or AMP cells onto the nasal mucosa adjacent to the foramina of the cribriform plate located at the superior aspect of the nasal cavity, andb) allowing the ACCS or AMP cells to permeate through the foramina into the cranial cavity at the location of the optic nerve. The field of the invention is directed to methods for preventing and/or treating optic neuritis. The ...

Methods for treating cartilage disorders, diseases, and injuries

The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. 1. A method for treating cartilage diseases , disorders and injuries in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a composition selected from the group consisting of a CFS composition , Amnion-derived Multipotent Progenitor (AMP) cells , AMP-NP cells and AMP-AF cells.2. The method of wherein the treatment reduces the inflammation associated with cartilage diseases claim 1 , disorders and injuries.3. The method of wherein the CFS composition is selected from the group consisting of ACCS claim 1 , ACCS-NP and ACCS-AF.4. The method of wherein the cartilage disease claim 1 , disorder or injury is selected from the group consisting of osteoarthritis claim 1 , rheumatoid arthritis claim 1 , gouty arthritis claim 1 , psoriatic arthritis claim 1 , intervertebral disc herniation claim 1 , degenerative disc disease claim 1 , spinal stenosis claim 1 , lumbar scoliosis claim 1 , chondrodystrophies claim 1 , traumatic rupture or detachment claim 1 , achondroplasty claim 1 , costochondritis claim 1 , relapsing polychonditis destruction claim 1 , and ankylosing spondylitis.5. A method for promoting the growth or enhancing the survival of nucleus pulposus (NP) cells in a degenerating intervertebral disc comprising administering to the degenerating intervertebral disc a therapeutically effective amount of a composition selected from the group consisting of a CFS composition claim 1 , AMP cells claim 1 , AMP-NP cells and AMP-AF cells.6. The ...

Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury

The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light.

Modulating Ischemic Injury

The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents. 120.-. (canceled)21. A method for modulating ischemic injury in an ischemic lung , the method comprising the step of administering a composition comprising Amnion-derived Cellular Cytokine Solution (ACCS) to the ischemic lung such that the ischemic injury is modulated , wherein the ACCS is formulated for spray administration.22. The method of wherein the ACCS is further formulated for sustained-release claim 21 , targeted-release claim 21 , timed-release claim 21 , or extended-release.23. A method for modulating ischemic injury in an ischemic blood vessel claim 21 , the method comprising the step of administering a composition comprising ACCS to the ischemic blood vessel such that the ischemic injury is modulated.24. The method of wherein the ACCS is formulated for sustained-release claim 23 , targeted-release claim 23 , timed-release claim 23 , or extended-release.25. The method of wherein the ACCS is administered by a route selected from the group consisting of intravenous claim 23 , intramuscular claim 23 , intraarterial claim 23 , intradermal claim 23 , intraperitoneal claim 23 , subcutaneous claim 23 , and infusion.26. A method for modulating ischemic injury in donated tissues or organs that have been harvested for transplant claim 23 , the method comprising the step of perfusing and/or immersing the donated ...

Solenoid actuated continuously variable shock absorber

A shock absorber includes a pressure tube with a piston slidably disposed therein. A separate valve includes a fluid circuit for fluid low in rebound and a fluid circuit for fluid flow in compression. Each fluid circuit includes a variable orifice which allows selection between a firm rebound with a soft compression, a soft rebound with a soft compression, and a soft rebound with a firm compression. Each variable orifice is in communication with a blowoff valve in such a manner that they provide a variable blowoff feature to the blowoff valves.

Independently tunable variable bleed orifice

A shock absorber includes a valve assembly with a low speed valving system and a high speed valving system. Both systems control fluid flow through the respective valve assembly for fluid flow in the same direction. The low speed valving system is independently tunable in order to provide low speed damping to improve both the vehicle control and handling. The independent tuning of the low speed valving system allows the optimization of the low speed valving system in relation to the high speed valving system as well as the independent tuning of the high speed valving system in relation to the low speed valving system. The independent tuning of the two systems allow the achievement of a smooth transition between the two systems. The dual valving systems can be incorporated into the piston for a compression stroke, be incorporated into the piston for an extension stroke, or two dual valving systems can be incorporated into the piston for compression and extension strokes.

Methods for accelerating the healing of connective tissue injuries and disorders

The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS).

Wound healing device

The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix.

Shock absorber

(57)【要約】 【課題】 開放したとき、ショックアブソーバの伸長運 動中および圧縮運動中に柔らかい減衰特性を提供するバ イパス流通路を備えたショックアブソーバを提供するこ と。 【解決手段】 ショックアブソーバ１０がピストン１２ およびベース弁組立体に通常の流体弁を有し、このベー ス弁組立体は、ショックアブソーバの堅い減衰特性を提 供するように構成されている。ステッパ弁組立体は、上 方作業室２０とリザーバ室との間にバイパス流通路を有 し、この流通路は、開放したとき、ショックアブソーバ の伸長運動中に柔らかい減衰特性を提供する。またステ ッパ弁組立体は、下方作業室２２とリザーバ室２４との 間にバイパス流通路を有し、この流通路は、開放したと き、ショックアブソーバ１０の圧縮運動中に柔らかい減 衰特性を提供する。ステッパ弁組立体は、バイパス流通 路を選択的に開閉し、ショックアブソーバ１０を車の条 件に対応するようにする。

Infinitely adjustable shock absorber

Stoßdämpfer mit: einem Innenrohr (16), das einen Arbeitsraum bildet, einem Außenrohr (18), das das Innenrohr umgibt und hierbei eine Reservekammer (24) zwischen dem Innenrohr und Außenrohr bildet, einer Kolbenstange (14), die durch das Innenrohr (16) verläuft und sich in den Arbeitsraum erstreckt, einem Kolben (12), der in dem Innenrohr (16) gleitend gelagert und mit der Kolbenstange (14) verbunden ist, den Arbeitsraum in eine obere Arbeitskammer (20) und eine untere Arbeitskammer (22) unterteilt und eine Kolbenventilanordnung (114, 116) zum Steuern der Strömung zwischen der oberen und unteren Arbeitskammer aufweist, einer Bodenventilanordnung (26), die zwischen der Reservekammer (24) und der unteren Arbeitskammer (22) angeordnet ist, um die Strömung zwischen der Reservekammer (24) und der unteren Arbeitskammer (22) zu steuern, einer ersten Bypassventil-Anordnung (32-36,46), die in einem ersten Strömungskanal (32, 36, 78, 82) zwischen der Reservekammer (24) und der oberen Arbeitskammer (20) angeordnet ist, einer zweiten... Shock absorber with: an inner tube (16) forming a working space, an outer tube (18) surrounding the inner tube and thereby forming a reserve chamber (24) between the inner tube and the outer tube, a piston rod (14) extending through the inner tube (16) and extending into the working space, a piston (12) which is slidably mounted in the inner tube (16) and connected to the piston rod (14) divides the working space into an upper working chamber (20) and a lower working chamber (22) and a piston valve arrangement (114, 116) for controlling the flow between the upper and lower working chambers, a bottom valve assembly (26) disposed between the reserve chamber (24) and the lower working chamber (22) to control the flow between the reserve chamber (24) and the lower working chamber (22), a first bypass valve arrangement (32-36, 46) arranged in a first flow channel (32, 36, 78, 82) between the reserve chamber (24) and the upper working chamber (20), a ...

Adjustable shock absorber

Magnetventilgesteuerter stufenlos einstellbarer Stossdämpfer

Modeling wound healing

Provided are methods of simulating tissue healing. The methods comprise using a mechanistic computer model of the interrelated effects of inflammation, tissue damage or dysfunction and tissue healing to predict an outcome of healing of damaged tissue in vivo, thereby predicting the outcome of healing of damaged tissue in vivo. Implementations of these methods on a computing device also are provided. Non-limiting examples of diseases and/or conditions that are amenable to simulation according to the methods described herein include: a diabetes, diabetic foot ulcers, necrotizing enterocolitis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, restenosis (post-angioplasty or stent implantation), incisional wounding, excisional wounding, surgery, accidental trauma, pressure ulcer, stasis ulcer, tendon rupture, vocal fold phonotrauma, otitis media and pancreatitis.

Modeling wound healing

Provided are methods of simulating tissue healing. The methods comprise using a mechanistic computer model of the interrelated effects of inflammation, tissue damage or dysfunction and tissue healing to predict an outcome of healing of damaged tissue in vivo, thereby predicting the outcome of healing of damaged tissue in vivo. Implementations of these methods on a computing device also are provided. Non-limiting examples of diseases and/or conditions that are amenable to simulation according to the methods described herein include: a diabetes, diabetic foot ulcers, necrotizing enterocolitis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, restenosis (post-angioplasty or stent implantation), incisional wounding, excisional wounding, surgery, accidental trauma, pressure ulcer, stasis ulcer, tendon rupture, vocal fold phonotrauma, otitis media and pancreatitis.

Modeling wound healing

Provided are methods of simulating tissue healing. The methods comprise using a mechanistic computer model of the interrelated effects of inflammation, tissue damage or dysfunction and tissue healing to predict an outcome of healing of damaged tissue in vivo, thereby predicting the outcome of healing of damaged tissue in vivo. Implementations of these methods on a computing device also are provided. Non-limiting examples of diseases and/or conditions that are amenable to simulation according to the methods described herein include: a diabetes, diabetic foot ulcers, necrotizing enterocolitis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, restenosis (post-angioplasty or stent implantation), incisional wounding, excisional wounding, surgery, accidental trauma, pressure ulcer, stasis ulcer, tendon rupture, vocal fold phonotrauma, otitis media and pancreatitis.

Wound healing device and method

The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.

Wound healing device and method

The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.

Methods for accelerating the healing of connective tissue injuries and disorders

The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS).